Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL indicated for the treatment of Duchenne...
Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies...
Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen...
Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Bortezomib for Injection in the United States. The product contains the same active ingredient as VELCADE®, as approved by...
WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), announced the successful closing of an oversubscribed Series D financing...
Rugiet, the performance medicine company that’s helped more than 500,000 men take control of their health, announced the expansion of its treatment areas to include longevity. Rugiet is bringing its physician-prescribed standards to an emerging...
Bayer announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for contrast-enhanced magnetic resonance imaging (MRI) to...
The EVERY Company ("EVERY"), a leader in highly functional egg proteins produced via precision fermentation, announced a significant manufacturing expansion with its strategic partner, Huvepharma, a global pharmaceutical company with a focus on...
Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to...
The DIA 2026 Global Annual Meeting is evolving, just like the life sciences community it serves. Join global innovators, regulators, academics, patient advocates, and industry leaders for an all-new experience designed to inspire, engage, and...
AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL...
ELASTEN®, Germany's 1 liquid collagen supplement and a global leader in clinically studied ingestible skincare, announced a year-long partnership with renowned board-certified dermatologist, media expert, and trusted authority in cosmetic and...
NurtureBio, a maternal and child wellness company focused on science-backed solutions for infant gut health, announced a collaboration with Lallemand Health Solutions, the company's key partner involved with its newly launched synbiotic blend for...
Kyowa Hakko, a global leader in health ingredient innovation and manufacturer of branded ingredient Setria® Glutathione, announced that a supplement featuring Setria has been approved for sale in Chile through the Secretaría Regional Ministerial...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions Under the theme “One Roquette for Innovations,” Roquette’s Health & Pharma...
X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, announced the commercial launch of its XT-NoVo® and TimeSeal® platform. This advanced end-to-end...
Johnson & Johnson is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients...
VERTANICAL announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The authorization marks a major milestone for VERTANICAL and highlights...
Alpha Cognition Inc. a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral,...
